Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efmarodocokin Alfa + SOC for aGVHD Prevention in HSCT
NCT04539470Phase 1Completed
- Sponsor
- Genentech
- Start
- Nov 2020
- Primary completion
- Feb 2023
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label trial of efmarodocokin alfa in Acute Graft-Versus-Host Disease (aGvHD) (3 arms), sponsored by Genentech. Primary endpoints: Number of Participants with Adverse Events by Severity at 365 days, Change from Baseline in Respiratory Rate Over Time at 139 days and 7 more. Started Nov 2020; status: completed.
02
Drugs
efmarodocokin alfa
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NCT04539470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04539470.